The synergistic anticancer effects of ReoT3D, CPT-11, and BBI608 on murine colorectal cancer cells.
Animals
Apoptosis Regulatory Proteins
/ genetics
Benzofurans
/ pharmacology
Biological Products
Cell Cycle Proteins
/ genetics
Cell Line
Cell Line, Tumor
Cell Movement
/ drug effects
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Colorectal Neoplasms
/ genetics
Combined Modality Therapy
Drug Synergism
Gene Expression Regulation, Neoplastic
/ drug effects
Herpesvirus 1, Human
Irinotecan
/ pharmacology
Mice
Naphthoquinones
/ pharmacology
Oncolytic Viruses
/ physiology
Proto-Oncogene Proteins p21(ras)
/ genetics
Reoviridae
/ physiology
STAT3 Transcription Factor
/ genetics
Colorectal cancer
Combination
Irinotecan
Napabucasin
Oncolytic reovirus
Journal
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
ISSN: 2008-2231
Titre abrégé: Daru
Pays: Switzerland
ID NLM: 101125969
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
23
03
2020
accepted:
23
07
2020
pubmed:
18
8
2020
medline:
28
8
2021
entrez:
18
8
2020
Statut:
ppublish
Résumé
Many types of oncolytic viruses (OVs) were enrolled in clinical trials. Recently, an OV named Talimogene laherparepvec approved for the treatment of melanoma. This achievement highlighted the clinical application of OVs. Scientists focus on using these anticancer agents in combination with the current or/and new anticancer chemotherapeutics. They aim to increase the oncolytic effect of a new approach for the treatment of cancer cells. The present study aimed to assess the anticancer impacts of ReoT3D, irinotecan (CPT-11), and napabucasin (BBI608) against murine colorectal cancer cells (CT26). They are assessed alone and in combination with each other. Here, oncolytic reovirus was propagated and titrated. Then MTT assay was carried out to assess the toxicity of this OV and chemotherapeutics effect on CT26 cells. The anticancer effects of ReoT3D, CPT-11, and BBI608, alone and simultaneously, on CT26 cell line, were assessed by the induction of apoptosis, cell cycle arrest, colony-forming, migration, and real-time PCR experiments. Alone treatment with ReoT3D, CPT-11, and BBI608 led to effectively inducing of apoptosis, cell cycle arrest, and apoptotic genes expression level and significantly reduce of colony-forming, migration, and anti-apoptotic genes expression rate. Importantly, the maximum anticancer effect against CT26 cell line was seen upon combination ReoT3D, CPT-11, and BBI608 treatment. The present study highlights that combination of ReoT3D, CPT-11, and BBI560 showed synergistic anticancer activity against CT26 cell line. This modality might be considered as a new approach against colorectal cancer (CRC) in the in vivo and clinical trial investigations.
Sections du résumé
BACKGROUND
BACKGROUND
Many types of oncolytic viruses (OVs) were enrolled in clinical trials. Recently, an OV named Talimogene laherparepvec approved for the treatment of melanoma. This achievement highlighted the clinical application of OVs. Scientists focus on using these anticancer agents in combination with the current or/and new anticancer chemotherapeutics. They aim to increase the oncolytic effect of a new approach for the treatment of cancer cells.
OBJECTIVES
OBJECTIVE
The present study aimed to assess the anticancer impacts of ReoT3D, irinotecan (CPT-11), and napabucasin (BBI608) against murine colorectal cancer cells (CT26). They are assessed alone and in combination with each other.
METHODS
METHODS
Here, oncolytic reovirus was propagated and titrated. Then MTT assay was carried out to assess the toxicity of this OV and chemotherapeutics effect on CT26 cells. The anticancer effects of ReoT3D, CPT-11, and BBI608, alone and simultaneously, on CT26 cell line, were assessed by the induction of apoptosis, cell cycle arrest, colony-forming, migration, and real-time PCR experiments.
RESULTS
RESULTS
Alone treatment with ReoT3D, CPT-11, and BBI608 led to effectively inducing of apoptosis, cell cycle arrest, and apoptotic genes expression level and significantly reduce of colony-forming, migration, and anti-apoptotic genes expression rate. Importantly, the maximum anticancer effect against CT26 cell line was seen upon combination ReoT3D, CPT-11, and BBI608 treatment.
CONCLUSION
CONCLUSIONS
The present study highlights that combination of ReoT3D, CPT-11, and BBI560 showed synergistic anticancer activity against CT26 cell line. This modality might be considered as a new approach against colorectal cancer (CRC) in the in vivo and clinical trial investigations.
Identifiants
pubmed: 32803686
doi: 10.1007/s40199-020-00361-w
pii: 10.1007/s40199-020-00361-w
pmc: PMC7704878
doi:
Substances chimiques
Apoptosis Regulatory Proteins
0
Benzofurans
0
Biological Products
0
Cell Cycle Proteins
0
Naphthoquinones
0
STAT3 Transcription Factor
0
Stat3 protein, mouse
0
napabucasin
0
talimogene laherparepvec
0
Irinotecan
7673326042
Hras protein, mouse
EC 3.6.5.2
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
555-565Subventions
Organisme : Tarbiat Modares University
ID : Med-76015
Organisme : National Institute for Medical Research Development
ID : 957970
Références
Oncotarget. 2014 May 15;5(9):2807-19
pubmed: 24798549
Drugs. 2017 Jul;77(10):1091-1103
pubmed: 28573435
Oncolytic Virother. 2018 Jun 14;7:53-63
pubmed: 29942799
Can J Vet Res. 2016 Jan;80(1):21-31
pubmed: 26733729
Cancer Med. 2016 Jun;5(6):1251-8
pubmed: 26899963
Clin Cancer Res. 2008 Feb 1;14(3):912-23
pubmed: 18245555
Ann Oncol. 2002 Dec;13(12):1841-51
pubmed: 12453851
Cell Res. 2008 Feb;18(2):254-67
pubmed: 18227858
Clin Cancer Res. 2009 Oct 1;15(19):6158-66
pubmed: 19773377
Clin Cancer Res. 2010 Nov 15;16(22):5564-72
pubmed: 20926400
Front Microbiol. 2015 Sep 02;6:886
pubmed: 26388843
Clin Cancer Res. 2020 Jan 1;26(1):71-81
pubmed: 31694832
J Neurovirol. 2010 Jul;16(4):306-17
pubmed: 20626234
Cancer Sci. 2016 Oct;107(10):1373-1379
pubmed: 27486853
Mol Cancer Ther. 2016 May;15(5):767-73
pubmed: 27197256
Cell Cycle. 2005 Apr;4(4):556-9
pubmed: 15753655
J Virol. 2005 Dec;79(23):14981-5
pubmed: 16282499
Cancer Immunol Res. 2014 Apr;2(4):295-300
pubmed: 24764576
Biotechniques. 1997 Sep;23(3):525-31
pubmed: 9298227
Virology. 1969 Dec;39(4):791-810
pubmed: 4311639
Cancer Treat Rev. 2006 Nov;32(7):491-503
pubmed: 16959432
Curr Treat Options Oncol. 2015 Jan;16(1):317
pubmed: 25648541
ACS Infect Dis. 2018 Oct 12;4(10):1448-1467
pubmed: 30152676
Cytometry A. 2007 Mar;71(3):125-31
pubmed: 17252584
Clin Cancer Res. 2002 May;8(5):994-1003
pubmed: 12006511
Cancer Biother Radiopharm. 2017 Jun;32(5):149-160
pubmed: 28622036
J Virol. 2000 Oct;74(20):9562-70
pubmed: 11000227
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
Cancers (Basel). 2018 May 25;10(6):
pubmed: 29799479
Cancer. 2016 Mar 15;122(6):875-83
pubmed: 26709987
PLoS One. 2017 Jan 18;12(1):e0168233
pubmed: 28099441
Tumour Biol. 2016 Mar;37(3):3155-61
pubmed: 26427658
World J Gastroenterol. 2003 Feb;9(2):193-200
pubmed: 12532430
Eur J Pharmacol. 2019 Jul 15;855:252-261
pubmed: 31085238
Clin Oncol (R Coll Radiol). 2008 Sep;20(7):548-54
pubmed: 18583112
mBio. 2013 May 14;4(3):e00178-13
pubmed: 23674612
J Cell Biochem. 2017 Aug;118(8):1979-1983
pubmed: 28109136
Cell J. 2020 Oct;22(3):283-292
pubmed: 31863653
JAMA Oncol. 2017 Jun 1;3(6):841-849
pubmed: 27441411
Int J Cancer. 2020 Feb 1;146(3):749-758
pubmed: 30968402
Cytometry. 1998 Jan 1;31(1):1-9
pubmed: 9450519
Oncogene. 2006 Jan 12;25(2):165-75
pubmed: 16170360